Targeting inflammation in the treatment of type 2 diabetes: time to start (Q38214020)

31 August 2017

title

Targeting inflammation in the treatment of type 2 diabetes: time to start (English)

1 reference

31 August 2017

0 references

0 references

Marc Y Donath

1

1 reference

31 August 2017

publication date

23 May 2014

1 reference

Nature Reviews Drug Discovery

31 August 2017

published in

1 reference

31 August 2017

volume

13

1 reference

31 August 2017

issue

6

1 reference

31 August 2017

page(s)

465-476

1 reference

Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible?

31 August 2017

cites work

1 reference

Mechanisms linking obesity to insulin resistance and type 2 diabetes

31 March 2020

1 reference

Islet growth and development in the adult

31 March 2020

1 reference

Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance

31 March 2020

1 reference

Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes

31 March 2020

1 reference

Five stages of evolving beta-cell dysfunction during progression to diabetes

31 March 2020

1 reference

Islet beta cell failure in type 2 diabetes

31 March 2020

1 reference

Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes

31 March 2020

1 reference

Endoplasmic reticulum stress and the development of diabetes: a review

31 March 2020

1 reference

Nutrient sensing and inflammation in metabolic diseases

31 March 2020

1 reference

Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes

31 March 2020

1 reference

Pancreatic islet inflammation in type 2 diabetes: from alpha and beta cell compensation to dysfunction.

31 March 2020

1 reference

Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1β production and β-cell dysfunction.

31 March 2020

1 reference

IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction.

31 March 2020

1 reference

Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes

31 March 2020

1 reference

Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes

31 March 2020

1 reference

Thioredoxin-interacting protein mediates ER stress-induced β cell death through initiation of the inflammasome

31 March 2020

1 reference

IRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress.

31 March 2020

1 reference

Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets

31 March 2020

1 reference

Thioredoxin-interacting protein links oxidative stress to inflammasome activation

31 March 2020

1 reference

Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I.

31 March 2020

1 reference

Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance

31 March 2020

1 reference

FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells from apoptosis to cell replication

31 March 2020

1 reference

Increased number of islet-associated macrophages in type 2 diabetes.

31 March 2020

1 reference

Islet-associated macrophages in type 2 diabetes.

31 March 2020

1 reference

Association of proinflammatory cytokines and islet resident leucocytes with islet dysfunction in type 2 diabetes

31 March 2020

1 reference

Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation.

31 March 2020

1 reference

Leptin-regulated endocannabinoids are involved in maintaining food intake

31 March 2020

1 reference

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

31 March 2020

1 reference

Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans

31 March 2020

1 reference

Affinity-purified human interleukin I is cytotoxic to isolated islets of Langerhans

31 March 2020

1 reference

Endoplasmic reticulum stress and the inflammatory basis of metabolic disease

31 March 2020

1 reference

The relationship between metabolism and the autophagy machinery during the innate immune response

31 March 2020

1 reference

Relationship between adipocyte size and adipokine expression and secretion

31 March 2020

1 reference

The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity

31 March 2020

1 reference

Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1beta transcription in human adipose tissue

31 March 2020

1 reference

Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling

31 March 2020

1 reference

Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans

31 March 2020

1 reference

Obesity is associated with macrophage accumulation in adipose tissue

31 March 2020

1 reference

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

31 March 2020

1 reference

Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice

31 March 2020

1 reference

Emerging role of adipose tissue hypoxia in obesity and insulin resistance

31 March 2020

1 reference

Pathways in microbe-induced obesity

31 March 2020

1 reference

Obesity alters gut microbial ecology

31 March 2020

1 reference

An obesity-associated gut microbiome with increased capacity for energy harvest

31 March 2020

1 reference

Microbial ecology: human gut microbes associated with obesity

31 March 2020

1 reference

Metabolic endotoxemia initiates obesity and insulin resistance

31 March 2020

1 reference

Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice

31 March 2020

1 reference

A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways

31 March 2020

1 reference

The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance

31 March 2020

1 reference

Immunological and inflammatory functions of the interleukin-1 family

31 March 2020

1 reference

Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance

31 March 2020

1 reference

Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM.

31 March 2020

1 reference

Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes

31 March 2020

1 reference

Effects of etanercept in patients with the metabolic syndrome

31 March 2020

1 reference

TNF-α Antagonism with Etanercept Decreases Glucose and Increases the Proportion of High Molecular Weight Adiponectin in Obese Subjects with Features of the Metabolic Syndrome

31 March 2020

1 reference

Improvement of insulin sensitivity in insulin resistant subjects during prolonged treatment with the anti-TNF-alpha antibody infliximab

31 March 2020

1 reference

Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis

31 March 2020

1 reference

Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation

31 March 2020

1 reference

Improved insulin sensitivity by anti-TNFalpha antibody treatment in patients with rheumatic diseases

31 March 2020

1 reference

Effect of etanercept on insulin sensitivity in nine patients with psoriasis

31 March 2020

1 reference

Infliximab in the treatment of Crohn disease and type 1 diabetes

31 March 2020

1 reference

Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis

31 March 2020

1 reference

Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy

31 March 2020

1 reference

Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.

31 March 2020

1 reference

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

31 March 2020

1 reference

Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study

31 March 2020

1 reference

Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes

31 March 2020

1 reference

Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial

31 March 2020

1 reference

Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.

31 March 2020

1 reference

Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes

31 March 2020

1 reference

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

31 March 2020

1 reference

Salsalate improves glycemia and inflammatory parameters in obese young adults

31 March 2020

1 reference

Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes

31 March 2020

1 reference

The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study.

31 March 2020

1 reference

The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial

31 March 2020

1 reference

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial

31 March 2020

1 reference

A randomised trial of salsalate for insulin resistance and cardiovascular risk factors in persons with abnormal glucose tolerance

31 March 2020

1 reference

Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes.

31 March 2020

1 reference

Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial

31 March 2020

1 reference

Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1α and sterile vascular inflammation in atherosclerosis

31 March 2020

1 reference

Monocyte chemoattractant protein 1 in obesity and insulin resistance

31 March 2020

1 reference

MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity

31 March 2020

1 reference

CCR2 modulates inflammatory and metabolic effects of high-fat feeding

31 March 2020

1 reference

Muscle as an endocrine organ: focus on muscle-derived interleukin-6.

31 March 2020

1 reference

Muscles, exercise and obesity: skeletal muscle as a secretory organ

31 March 2020

1 reference

Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase

31 March 2020

1 reference

Counterpoint: Interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis

31 March 2020

1 reference

Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis

31 March 2020

1 reference

A stress signaling pathway in adipose tissue regulates hepatic insulin resistance

31 March 2020

1 reference

Point-counterpoint: Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis

31 March 2020

1 reference

Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action

31 March 2020

1 reference

Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.

31 March 2020

1 reference

How obesity causes diabetes: not a tall tale

31 March 2020

1 reference

IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.

31 March 2020

1 reference

Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease

31 March 2020

1 reference

Mammalian sirtuins: biological insights and disease relevance

31 March 2020

1 reference

Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome

31 March 2020

1 reference

When metabolism met immunology.

31 March 2020

1 reference

Identification of a SIRT1 mutation in a family with type 1 diabetes

31 March 2020

1 reference

Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice

31 March 2020

1 reference

AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity

31 March 2020

1 reference

The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity

31 March 2020

1 reference

Poly(ADP-ribose) polymerase 1 at the crossroad of metabolic stress and inflammation in aging

31 March 2020

1 reference

Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells.

31 March 2020

1 reference

Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes.

31 March 2020

1 reference

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

31 March 2020

1 reference

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

31 March 2020

1 reference

Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway

31 March 2020

1 reference

The role of JNK proteins in metabolism

31 March 2020

1 reference

Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway

31 March 2020

1 reference

Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients

31 March 2020

1 reference

Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model

31 March 2020

1 reference

Exenatide exerts a potent antiinflammatory effect

31 March 2020

1 reference

Sitagliptin exerts an antinflammatory action

31 March 2020

1 reference

Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay

31 March 2020

1 reference

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

31 March 2020

1 reference

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

31 March 2020

1 reference

Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes

31 March 2020

1 reference

Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells

31 March 2020

1 reference

Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes.

31 March 2020

1 reference

HMG-CoA reductase inhibition induces IL-1beta release through Rac1/PI3K/PKB-dependent caspase-1 activation

31 March 2020

1 reference

Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1.

31 March 2020

1 reference

A role for geranylgeranylation in interleukin-1beta secretion

31 March 2020

1 reference

HMG-CoA reductase inhibitors activate caspase-1 in human monocytes depending on ATP release and P2X7 activation

31 March 2020

1 reference

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

31 March 2020

1 reference

Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes

31 March 2020

1 reference

Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms

31 March 2020

1 reference

Aldosterone excess impairs first phase insulin secretion in primary aldosteronism.

31 March 2020

1 reference

Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation

31 March 2020

1 reference

Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension

31 March 2020

1 reference

Angiotensin blockade in diabetic patients decreases insulin resistance-associated low-grade inflammation

31 March 2020

1 reference

ANG II receptor antagonists as modulators of macrophages polarization

31 March 2020

1 reference

Telmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed mice

31 March 2020

1 reference

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

31 March 2020

1 reference

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

31 March 2020

1 reference

Blocking interleukin-1β induces a healing-associated wound macrophage phenotype and improves healing in type 2 diabetes

31 March 2020

1 reference

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

31 March 2020

1 reference

Gout-associated uric acid crystals activate the NALP3 inflammasome

31 March 2020

1 reference

How interleukin-1β induces gouty arthritis

31 March 2020

1 reference

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

31 March 2020

1 reference

Psoriasis severity and the prevalence of major medical comorbidity: a population-based study

31 March 2020

1 reference

Inflammation in atherosclerosis: from pathophysiology to practice

31 March 2020

1 reference

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

31 March 2020

1 reference

Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity

31 March 2020

1 reference

12 December 2020

Point-counterpoint: Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis

1 reference

12 December 2020

No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients

1 reference

12 December 2020

Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis.

1 reference

12 December 2020

Point-counterpoint: Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD4275

1 reference

31 August 2017

1 reference